Egetis Therapeutics
Egetis Therapeutics AB is a commercial-stage biopharmaceutical enterprise headquartered in Stockholm, Sweden. The company focuses on the development and commercialization of innovative treatments for rare and severe orphan diseases. Its clinical development pipeline features lead drug candidates designed to address metabolic conditions and pediatric endocrine disorders with high unmet medical needs. Principal revenue is earned through commercial pharmaceutical sales, early access programs, and licensing agreements. The firm serves specialized clinical treatment centers, endocrinologists, and rare disease patients across European and international markets. Egetis Therapeutics AB is listed on Nasdaq Stockholm.
3 of the funds FundTelligence covers report a position in Egetis Therapeutics.
- Legal name
- Egetis Therapeutics AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 3
Funds holding Egetis Therapeutics
- Storebrand Sverige Småbolag Plus — Storebrand · 0.14 % (full portfolio disclosed, October 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.11 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.04 % (full portfolio disclosed, October 2026)